Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 7, 2026Brazilian Journal of OncologyOpen Access

Standard or Modified Gemcitabine Plus Nab-Paclitaxel (GnP) in the First-Line Treatment of Patients with Metastatic Pancreatic Adenocarcinoma (MPA): A Single-Center Analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

VJVictor Hugo Fonseca de JesusFMFrancisco de Assis MaiaCSCícero Gonzaga Santos

Discussion

Loading...

Member takes

Overview

Retrospective analysis compares standard and modified gemcitabine with nab-paclitaxel effectiveness in Latin American metastatic pancreatic adenocarcinoma patients, indicating similar outcomes.

Key Points

  • To evaluate the effectiveness and safety of standard versus modified gemcitabine and nab-paclitaxel in treatment of metastatic pancreatic adenocarcinoma in Latin Americans.
  • Retrospective, unicentric analysis
  • Included chemotherapy-naïve patients diagnosed with metastatic pancreatic adenocarcinoma from 2015 to 2022
  • Compared clinical characteristics and treatment outcomes between standard and modified GnP.
  • Standard GnP showed an overall response rate of 28.6% and disease control rate of 57.1% vs. 11.8% and 58.8% for modified GnP.
  • Median overall survival for standard and modified GnP was 10.1 vs. 12.1 months (p=0.739) with no significant difference.
  • Lower rates of grade 3 or higher neutropenia were observed in modified GnP (5.9% vs. 28.6%; p=0.078).

Cite This Study

Jesus et al. (2026) studied this question.

synapsesocial.com/papers/6a250baa7def13d035e1bb42https://doi.org/10.1055/s-0045-1814366
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Early results of the PASS-01 trial: Pancreatic adenocarcinoma signature stratification for treatment-01.2024 · 8 citations
  2. 2Projection of the number of new cases of pancreatic cancer in the world2024 · 2 citations
  3. 3Clinical Outcomes and Safety of Patients Treated with NAb-Paclitaxel Plus Gemcitabine in Metastatic Pancreatic Cancer: The NAPA Study2020 · 12 citations
  4. 4Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer2019 · 79 citations
  5. 5Attenuated regimen of biweekly gemcitabine/nab-paclitaxel in patients aged 65 years or older with advanced pancreatic cancer2020 · 15 citations